Alchemy for the Mind

What is NAH? A novel cleavable prodrug that covalently links a CNS stimulant pharmacophore with a potent neurotrophic factor inducer (derived from Hericium erinaceus). Once in the body, NAH undergoes controlled enzymatic cleavage to release both payloads with tunable kinetics.

Dual-Action Mechanism

• Phase 1 (Acute – 0–4 hrs): Rapid release of stimulant moiety → ↑ dopamine & norepinephrine → laser focus, motivation, and executive function.

• Phase 2 (Sustained – 4–24+ hrs): Release of erinacine/hericenone scaffold → ↑ NGF & BDNF → neurite outgrowth, synaptic plasticity, and neuroregeneration.

Target Indications

• Attention-Deficit/Hyperactivity Disorder (ADHD/ADD)

• Mild Cognitive Impairment & early neurodegenerative conditions

• Healthy cognitive optimization (performance neurology)

Key Advantages

• Single daily dose (no polypharmacy)

• Built-in neuroprotection – not just symptom masking

• Tunable release via proprietary linker technology

• Potential for improved long-term brain health

Development Stage Provisional patent filed April 11, 2026 Detailed synthesis protocol validated in specification IND-enabling studies planned 2026–2027

Trismegistus Pharma – Founded by inventor Robert Caldwell Robertson III

Confidential – For Qualified Investors & Researchers Only

3. MISSION & VISION STATEMENT (About Us Page)

Our Mission To unlock human cognitive potential by creating medicines that do not merely treat symptoms — they rebuild the brain from within.

Our Vision A world where cognitive decline is optional, where focus is effortless, and where the ancient wisdom of nature’s neurotrophics is fused with modern pharmacology under the banner of Trismegistus — the thrice-great master of transformation.

Founding Story Born from the vision of inventor Robert Caldwell Robertson III, Trismegistus Pharma was created to bring NEUROAMPHECINE-HERICEN from provisional patent to patients who need it most.